Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07177677
PHASE1

A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder

Sponsor: Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.

View on ClinicalTrials.gov

Summary

This clinical trial aims to evaluate the safety and preliminary efficacy of intravenous administration of human bone marrow-derived mesenchymal stem cells (hBMMSCs) in patients with autism spectrum disorder (ASD).

Official title: Intravenous Injection of Human Bone Marrow Mesenchymal Stem Cell (hBMMSC) in the Treatment of Autism Spectrum Disorder (ASD): An Exploratory Study on the Safety and Preliminary Efficacy

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

42

Start Date

2025-09-30

Completion Date

2028-08-30

Last Updated

2025-09-17

Healthy Volunteers

No

Interventions

BIOLOGICAL

hBMMSC

Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.